Breast cancer susceptibility genes: BRCA1 and BRCA2

Medicine

Volumn 77, Issue 3, 1998, Pages 208-226

  Brody, Lawrence C ^a,b   Biesecker, Barbara Bowles ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CASE REPORT; DISEASE ASSOCIATION; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC COUNSELING; HUMAN; LIPID DIET; MENARCHE; NONSENSE MUTATION; ONCOGENE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALLELES; BRCA2 PROTEIN; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; EXONS; FEMALE; GENES, BRCA1; GENETIC SCREENING; HUMANS; LINKAGE (GENETICS); MIDDLE AGED; NEOPLASM PROTEINS; PEDIGREE; POINT MUTATION; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0031812658     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199805000-00006     Document Type: Review

References (231)

1. Abel KJ, Boehnke M, Prahalad M, Ho P, Flejter WL, Watkins M, VanderStoep J, Chandrasekharappa SC, Collins FS, Glover TW, Weber BL. A radiation hybrid map of the BRCA1 region of chromosome 17q12-q21. Genomics 17: 632-41, 1993.
2. Abel KJ, Xy J, Yin GY, Lyons RH, Meisler MH, Weber BL. Mouse Brca1: Localization sequence analysis and identification of evolutionary conserved domains. Hum Mol Genet 4: 2265-73, 1995.
3. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60: 505-14, 1997.
4. ACOG committee opinion. Breast-ovarian cancer screening. Number 176, October 1996. Committee on Genetics. The American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 56: 82-3, 1997.
5. Akashi-Tanaka S, Fukutomi T, Fukami A, Fujiki T. Male breast cancer in patients with a familial history of breast cancer. Surg Today 26: 975-79, 1996.
6. Albertsen HM, Smith SA, Mazoyer S, Fujimoto E, Stevens J, Williams B, Rodriguez P, Cropp CS, Slijepcevic P, Carlson M, et al. A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21. Nat Genet 7: 472-79, 1994.
7. American Cancer Society. Cancer Facts & Figures - 1997 [web site]. Atlanta, GA: http://www.cancer.org/, 1997.
8. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology; Genetic testing for cancer susceptibility. J Clin Oncol 14: 1730-36, 1996.
9. American Society of Human Genetics, Ad Hoc Committee on Genetic Testing for Breast and Ovarian Cancer. Statement on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 55: ii-iv, 1994.
10. Bennett LM, Haugen-Strano A, Cochran C, Brownlee HA, Fiedorek FT Jr, Wiseman RW. Isolation of the mouse homologue of BRCA1 and genetic mapping to mouse chromosome 11. Genomics 29: 576-81, 1995.
11. Berman DB, Wagner-Costalas J, Schultz DC, Lynch HT, Daly M, Godwin AK. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: A genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet 58: 1166-76, 1996.
12. Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 86: 1403-8, 1994.
13. Bertwistle D, Swift S, Marston NJ, Jackson LE, Grassland S, Crompton MR, Marshall CJ, Ashworth A. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res 57: 5485-88, 1997.
14. Bienstock RJ, Darden T, Wiseman R, Pedersen L, Barrett JC. Molecular modeling of the amino-terminal zinc ring domain of BRCA1. Cancer Res 56: 2539-45, 1996.
15. Biesecker BB. Psychological issues in cancer genetics. Semin Oncol Nurs 13: 129-34, 1997.
16. Biesecker BB, Boehnke M, Calzone K, Markel DS, Garber JE, Collins FS, Weber BL. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer [published erratum appears in JAMA 270: 832, 1993]. JAMA 269: 1970-74, 1993.
17. Billings PR, Kohn MA, de Cuevas M, Beckwith J, Alper JS, Natowicz MR. Discrimination as a consequence of genetic testing. Am J Hum Genet 50: 476-82, 1992.
18. Botkin JR, Croyle RT, Smith KR, Baty BJ, Lerman C, Goldgar DE, Ward JM, Flick BJ, Nash JE. A model protocol for evaluating the behavioral and psychosocial effects of BRCA1 testing. J Natl Cancer Inst 88: 872-82, 1996.
19. Bowcock AM, Anderson LA, Friedman LS, Black DM, Osborne-Lawrence S, Rowell SE, Hall JM, Solomon E, King MC. THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21. Am J Hum Genet 52: 718-22, 1993.
20. Boyd M, Harris F, McFarlane R, Davidson HR, Black DM. A human BRCA1 gene knockout [letter]. Nature 375: 541-42, 1995.
21. Breast Cancer Linkage Consortium. Pathology of familial breast cancer. Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349: 1505-10, 1997.
22. Broca PP. Traite des tumeurs. Paris: Asselin, 1866.
23. Brody LC, Abel KJ, Castilla LH, Couch FJ, McKinley DR, Yin G, Ho PP, Merajver S, Chandrasekharappa SC, Xu J, et al. Construction of a transcription map surrounding the BRCA1 locus of human chromosome 17. Genomics 25: 238-47, 1995.
24. Brody LC, and the Breast Cancer Information Core Steering Committee. The breast cancer information core: An online database [web site]. http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/, 1998.
25. Brown KD, Tagle DA. Molecular perspectives on cancer, the cell cycle and the inherited disorder ataxia-telangiectasia. Prog Clin Biol Res 396: 101-13, 1997.
26. Brown MA, Jones KA, Nicolai H, Bonjardim M, Black D, McFarlane R, de Jong P, Quirk JP, Lehrach H, Solomon E. Physical mapping, cloning, and identification of genes within a 500-kb region containing BRCA1. Proc Natl Acad Sci U S A 92: 4362-66, 1995.
27. Brown MA, Solomon E. Towards cloning the familial breast-ovarian cancer gene on chromosome 17. Curr Opin Genet Dev 4: 439-45, 1994.
28. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277: 997-1003, 1997.
29. Butler LM, Schubert E, Oddoux C, Morrow J, Reich E, Hull JL, Ostrer H, King M-C. Fifty percent of Jewish high-risk breast and ovarian cancer families are not explained by the three known BRCA1 or BRCA2 founder mutations while a 0.7% combined BRCA1 founder mutation frequency is reported in a Jewish cohort [Abstract 133]. Am J Hum Genet 59: A28, 1996.
30. Campbell IG, Nicolai HM, Foulkes WD, Senger G, Stamp GW, Allan G, Boyer C, Jones K, Bast RC Jr, Solomon E, et al. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum Mol Genet 3: 589-94, 1994.
31. Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, Garber JE, Boyd J, Lubin MB, Deshano ML, Brody LC, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 8: 387-91, 1994.
32. Chamberlain JS, Boehnke M, Frank TS, Kiousis S, Xu J, Guo SW, Hauser ER, Norum RA, Helmbold EA, Markel DS, et al. BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis. Am J Hum Genet 52: 792-98, 1993.
33. Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature 382: 678-79, 1996.
34. Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, Lee WH. The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J Biol Chem 271: 32863-8, 1996.
35. Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Von Hoff D, Osborne CK, Lee WH. Aberrant subcellular localization of BRCA1 in breast cancer. Science 270: 789-91, 1995.
36. Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 56: 3168-72, 1996.
37. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73: 643-51, 1994.
38. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 77: 2318-24, 1996.
39. Collins F, Galas D. A new five-year plan for the U.S. Human Genome Project. Science 262: 43-46, 1993.
40. Collins FS. BRCA1 - lots of mutations, lots of dilemmas. N Engl J Med 334: 186-88, 1996.
41. Collins FS. Positional cloning: Let's not call it reverse anymore. Nat Genet 1: 3-6, 1992.
42. Concannon P, Gatti RA. Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia. Hum Mutat 10: 100-7, 1997.
43. Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VL, Ashworth A. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 17: 423-30, 1997.
44. Connor F, Smith A, Wooster R, Stratton M, Dixon A, Campbell E, Tait TM, Freeman T, Ashworth A. Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene. Hum Mol Genet 6: 291-300, 1997.
45. Couch FJ, Castilla LH, Xu J, Abel KJ, Welcsh P, King SE, Wong L, Ho PP, Merajver S, Brody LC, et al. A YAC-, P1-, and cosmid-based physical map of the BRCA1 region on chromosome 17q21. Genomics 25: 264-73, 1995.
46. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 336: 1409-15, 1997.
47. Couch FJ, Fand LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L. Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, Daly M, Radford DM, Sedlacek S, Rommens J, Simard J, Garber J, Merajver S, Weber BL. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13: 123-25, 1996.
48. Couch FJ, Kiousis S, Castilla LH, Xu J, Chandrasekharappa SC, Chamberlain JS, Collins FS, Weber BL. Characterization of 10 new polymorphic dinucleotide repeats and generation of a high-density microsatellite-based physical map of the BRCA1 region of chromosome 17q21. Genomics 24: 419-24, 1994.
49. Croyle RT, Lerman C. Psychological impact of genetic testing. In: Croyle RT, ed. Psychosocial effects of screening for disease prevention and detection. New York: Oxford University Press, pp 11-38, 1995.
50. Croyle RT, Smith KR, Botkin JR, Baty B, Nash J. Psychological responses to BRCA1 mutation testing: Preliminary findings. Health Psychol 16: 63-72, 1997.
51. Daly MB, Lerman C. Ovarian cancer risk counseling: A guide for the practitioner. Oncology 7: 27-41, 1993.
52. Davies K, White M. Breakthrough: The race to find the breast cancer gene. New York: Wiley, 1996.
53. Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissenbach J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature 380: 152-54, 1996.
54. Dickson D. Open access to sequence data 'will boost hunt for breast cancer gene'. Nature 378: 425, 1995.
55. Diez O, Brunet J, Sanz J, del Rio E, Alonso MC, Baiget M. Differences in phenotypic expression of anew BRCA1 mutation in identical twins. Lancet 350: 713, 1997.
56. Durocher F, Shattuck-Eidens D, McClure M, Labrie F, Skolnick MH, Goldgar DE, Simard J. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet 5: 835-42, 1996.
57. Easton D. Breast cancer genes - what are the real risks? Nat Genet 16: 210-11, 1997.
58. Easton DF. The inherited component of cancer. Br Med Bull 50: 527-35, 1994.
59. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer Results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52: 678-701, 1993.
60. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265-71, 1995.
61. Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 25: 101-24, 1995.
62. Eeles RA, Stratton MR, Goldgar DE, Easton DF. The genetics of familial breast cancer and their practical implications. Eur J Cancer 30A: 1383-90, 1994.
63. Eng C, Vijg J. Genetic testing: The problems and the promise. Nat Biotechnol 15: 422-26, 1997.
64. Evans SC, Lozano G. The Li-Fraumeni syndrome: An inherited susceptibility to cancer. Mol Med Today 3: 390-95, 1997.
65. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334: 143-49, 1996.
66. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57: 1457-62, 1995.
67. Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, Jacobs I, Chenevix-Trench G, Ponder BA, Gayther SA. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 56: 3622-25, 1996.
68. Friedman LS, Ostermeyer EA, Lynch ED, Szabo CI, Anderson LA, Dowd P, Lee MK, Rowell SE, Boyd J, King MC. The search for BRCA1. Cancer Res 54: 6374-82, 1994.
69. Friedman LS, Ostermeyer EA, Lynch ED, Welcsh P, Szabo CI, Meza JE, Anderson LA, Dowd P, Lee MK, Rowell SE, et al. 22 genes from chromosome 17q21: Cloning, sequencing, and characterization of mutations in breast cancer families and tumors. Genomics 25: 256-63, 1995.
70. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8: 399-404, 1994.
71. Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode EL, Rowell SE, King MC. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 57: 1284-97, 1995.
72. Futreal PA, Cochran C, Marks JR, Iglehart JD, Zimmerman W, Barrett JC, Wiseman RW. Mutation analysis of the THRA1 gene in breast cancer: Deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line. Cancer Res 54: 1791-94, 1994.
73. Futreal PA, Cochran C, Rosenthal J, Miki Y, Swenson J, Hobbs M, Bennett LM, Haugen-Strano A, Marks J, Barrett JC, et al. Isolation of a diverged homeobox gene, MOX1, from the BRCA1 region on 17q21 by solution hybrid capture. Hum Mol Genet 3: 1359-64, 1994.
74. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120-22, 1994.
75. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1879-86, 1989.
76. Garfinkel L, Boring CC, Heath CW. Changing trends: An overview of breast cancer incidence and mortality. Cancer 74: 222-27, 1994.
77. Geller G, Bernhardt BA, Helzlsouer K, Holtzman NA, Stefanek M, Wilcox PM. Informed consent and BRCA1 testing. Nat Genet 11: 364, 1995.
78. Geller G, Botkin JR, Green MJ, Press N, Biesecker BB, Wilfond B, Grana G, Daly MB, Schneider K, Kahn MJ. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. Jama 277: 1467-74, 1997.
79. Ghosh S, Collins FS. The geneticist's approach to complex disease. Annu Rev Med 47: 333-53, 1996.
80. Glavac D, Dean M. Applications of heteroduplex analysis for mutation detection in disease genes. Hum Mutat 6: 281-87, 1995.
81. Goldgar DE, Cannon-Albright LA, Oliphant A, Ward JH, Linker G, Swensen J, Tran TD, Fields P, Uharriet P, Skolnick MH. Chromosome 17q linkage studies of 18 Utah breast cancer kindreds. Am J Hum Genet 52: 743-48, 1993.
82. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 12: 191-94, 1996.
83. Gudas JM, Li T, Nguyen H, Jensen D, Rauscher F Jr, Cowan KH. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ 7: 717-23, 1996.
84. Gudas JM, Nguyen H, Li T, Cowan KH. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 55: 4561-65, 1995.
85. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN. A radiation hybrid map of the human genome. Hum Mol Genet 5: 339-46, 1996.
86. Hailey BJ. Family history of breast cancer and screening behavior: An inverted u-shaped curve? Med Hypotheses 36: 397-403, 1991.
87. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85: 1009-23, 1996.
88. Hall JM, Friedman L, Guenther C, Lee MK, Weber JL, Black DM, King MC. Closing in on a breast cancer gene on chromosome 17q. Am J Hum Genet 50: 1235-42, 1992.
89. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250: 1684-89, 1990.
90. Hanssen AM, Fryns JP. Cowden syndrome. J Med Genet 32: 117-19, 1995.
91. Harshman K, Bell R, Rosenthal J, Katcher H, Miki Y, Swenson J, Gholami Z, Frye C, Ding W, Dayananth P, et al. Comparison of the positional cloning methods used to isolate the BRCA1 gene. Hum Mol Genet 4: 1259-66, 1995.
92. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. Growth retardation and tumour inhibition by BRCA1. Nat Genet 12: 298-302, 1996.
93. Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, Weber BL. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 273: 577-85, 1995.
94. Hudson KL, Rothenberg KH, Andrews LB, Kahn MJE, Collins FS. Genetic discrimination and health insurance: An urgent need for reform. Science 270: 391-93, 1995.
95. Humphrey JS, Salim A, Erdos MR, Collins FS, Brody LC, Klausner RD. Human BRCA1 inhibits growth in yeast: Potential use in diagnostic testing. Proe Natl Acad Sci U S A 94: 5820-25, 1997.
96. Jacob A, Kandpal G, Patanjali SR, Kandpal RP. Molecular cloning and expression pattern of genes from a 470 Kb region near BRCA1 locus on chromosome 17q21. Oncogene 11: 981-86, 1995.
97. Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R, Helou B, Tronick SR, Page DL, King MC, Holt JT. BRCA1 is secreted and exhibits properties of a granin. Nat Genet 12: 303-8, 1996.
98. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V, Barkardottir RB. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 56: 3663-65, 1996.
99. Johannsson O, Ostermeyer EA, Hakansson S, Friedman LS, Johansson U, Sellberg G, Brondum-Nielsen K, Sele V, Olsson H, King MC, Borg A. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet 58: 441-50, 1996.
100. Jones KA, Black DM, Brown MA, Griffiths BL, Nicolai HM, Chambers JA, Boryardim M, Xu CF, Boyd M, McFarlane R, et al. The detailed characterisation of a 400 kb cosmid walk in the BRCA1 region: Identification and localisation of 10 genes including a dual-specificity phosphatase. Hum Mol Genet 3: 1927-34, 1994.
101. Kainu T, Kononen J, Johansson O, Olsson H, Borg A, Isola J. Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization. Cancer Res 56: 2912-15, 1996.
102. Kamb A, Futreal PA, Rosenthal J, Cochran C, Harshman KD, Liu Q, Phelps RS, Tavtigian SV, Tran T, Hussey C, et al. Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1. Genomics 23: 163-67, 1994.
103. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80: 435-41, 1997.
104. Kash KM, Holland JC, Halper MS, Miller DG. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 84: 24-30, 1992.
105. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 276: 33-38, 1996.
106. Kiaris H, Spanakis N, Ergazaki M, Sourvinos G, Spandidos DA. Loss of heterozygosity at 9p and 17q in human laryngeal tumors. Cancer Lett 97: 129-34, 1995.
107. King MC, Rowell S, Love SM. Inherited breast and ovarian cancer. What are the risks? What are the choices? JAMA 269: 1975-80, 1993.
108. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761, 1997.
109. Knudson AG. Hereditary cancer: Two hits revisited. J Cancer Res Clin Oncol 122: 135-40, 1996.
110. Koonin EV, Altschul SF, Bork P. BRCA1 protein products: Functional motifs. Nat Genet 13: 266-68, 1996.
111. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal PA. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13: 238-40, 1996.
112. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 15: 177-202, 1997.
113. Lerman C, Biesecker B, Benkendorf JL, Kerner J, Gomez-Caminero A, Hughes C, Reed MM. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst 89: 148-57, 1997.
114. Lerman C, Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. Arch Intern Med 154: 609-16, 1994.
115. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 12: 843-50, 1994.
116. Lerman C, Daly M, Sands C, Balshem A, Lustbader E, Heggan T, Goldstein L, James J, Engstrom P. Mammography adherence and psychological distress among women at risk for breast cancer. J Natl Cancer Inst 85: 1074-80, 1993.
117. Lerman C, Kash K, Stefanek M. Younger women at increased risk for breast cancer: Perceived risk, psychological well-being and surveillance behavior. Monogr Natl Cancer Inst 16: 171-76, 1994.
118. Lerman C, Lustbader E, Rimer B, Daly M, Miller S, Sands C, Balshem A. Effects of individualized breast cancer risk counseling: A randomized trial. J Natl Cancer Inst 87: 286-92, 1995.
119. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 275: 1885-92, 1996.
120. Lerman C, Schwartz MD. Adherence and psychological adjustment among women at high risk for breast cancer. Breast Cancer Res Treat 28: 145-55, 1993.
121. Lerman C, Schwartz MD, Miller SM, Daly M, Sands C, Rimer BK. A randomized trial of breast cancer risk counseling: Interacting effects of counseling, educational level, and coping style. Health Psychol 15: 75-83, 1996.
122. Lindblom A, Skoog L, Andersen TI, Holstein S, Nordenskjold M, Larsson C. Four separate regions on chromosome 17 show loss of heterozygosity in familial breast carcinomas. Hum Genet 91: 6-12, 1993.
123. Lindblom A, Skoog L, Rotstein S, Werelius B, Larsson C, Nordenskjold M. Loss of heterozygosity in familial breast carcinomas. Cancer Res 53: 4356-61, 1993.
124. Liu CY, Flesken-Nikitin A, Li S, Zeng Y, Lee WH. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev 10: 1835-43, 1996.
125. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11: 1226-41, 1997.
126. Lynch HT, Watson P, Conway TA, Lynch JF, Slominski-Caster SM, Narod SA, Feunteun J, Lenoir G. DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med 153: 1979-87, 1993.
127. Mallory SB. Cowden syndrome (multiple hamartoma syndrome). Dermatol Clin 13: 27-31, 1995.
128. Marcus JN, Watson P, Page DL, Lynch HT. Pathology and heredity of breast cancer in younger women. Monogr Natl Cancer Inst 16: 23-34, 1994.
129. Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 44: 275-77, 1997.
130. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosh LA. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 11: 17-26, 1995.
131. Marshall E. The battle over BRCA1 goes to court; BRCA2 may be next. Science 278: 1874, 1997.
132. Marshall E. Gene tests get tested. Science 275: 782, 1997.
133. Mashal RD, Sklar J. Practical methods of mutation detection. Curr Opin Genet Dev 6: 275-80, 1996.
134. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, Goldgar DE, Ponder BA, Lenoir GM. A polymorphic stop codon in BRCA2. Nat Genet 14: 253-54, 1996.
135. McKusick VA. Editorial introduction: Reviews in molecular medicine [editorial]. Medicine (Baltimore) 74: 301-4, 1995.
136. 135a. McKusick VA. Mendelian inheritance in man: A catalog of human genes and genetic disorders. 12th ed. Baltimore: Johns Hopkins University Press, 1998.
137. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 9: 439-43, 1995.
138. Miesfeldt S, Turner BL, Lovell MA, Cooper MR, Lescallett J, Jones SM. A novel BRCA1 mutation in an identical twin pair with similar clinical histories. Cancer Genet Cytogenet 100: 43-48, 1998.
139. Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 13: 245-47, 1996.
140. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.
141. Miki Y, Swensen JJ, Hobbs MR, DeHoff BS, Rosteck PR, Skolnick MH, Neuhausen SL. A physical map encompassing GP2B, EPB3, D17S183, D17S78, D17S1183, and D17S1184. Genomics 25: 295-97, 1995.
142. Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T. Transcriptional activation functions in BRCA2. Nature 386: 772-73, 1997.
143. Mizuta R, LaSalle JM, Cheng HL, Shinohara A, Ogawa H, Copeland N, Jenkins NA, Lalande M, Alt FW. RAB22 and RAB163/mouse Brca2: Proteins that specifically interact with the RAD51 protein. Proc Natl Acad Sci U S A 94: 6927-32, 1997.
144. Montagna M, Serova O, Sylla BS, Feunteun J, Lenoir GM. A 100-kb physical and transcriptional map around the EDH17B2 gene: Identification of three novel genes and a pseudogene of a human homologue of the rat PRL-1 tyrosine phosphatase. Hum Genet 96: 532-38, 1995.
145. Mori T, Aoki T, Matsubara T, Iida F, Du X, Nishihira T, Mori S, Nakamura Y. Frequent loss of heterozygosity in the region including BRCA1 on chromosome 17q in squamous cell carcinomas of the esophagus. Cancer Res 54: 1638-40, 1994.
146. Motulsky AG. Jewish diseases and origins. Nat Genet 9: 99-101, 1995.
147. Muto MG, Cramer DW, Tangir J, Berkowitz R, Mok S. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 56: 1250-52, 1996.
148. Narod S, Tonin P, Lynch H, Watson P, Feunteun J, Lenoir G. Histology of BRCA1-associated ovarian tumours . Lancet 343: 236, 1994.
149. Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, Lenoir GM. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 338: 82-83, 1991.
150. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, Ponder BA, Weber BL, Garber JE, Birch JM, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 254-64, 1995.
151. National Action Plan on Breast Cancer. Position Paper: Hereditary susceptibility testing for breast cancer. J Clin Oncol 14: 1738-40, 1996.
152. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA 271: 785, 1994.
153. National Cancer Institute. Cancer Genetics Network, RFA: CA-97-004. NIH Guide 26(17), 1997.
154. Neish AS, Anderson SF, Schlegel BP, Wei W, Parvin P. Factors associated with the mammalian RNA polymerase II holoenzyme. Nucleic Acids Res 26: 847-53, 1998.
155. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 13: 126-28, 1996.
156. Neuhausen SL, Marshall CJ. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res 54: 6069-72, 1994.
157. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King MC, Goldgar DE. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: Results of an international study. Am J Hum Genet 58: 271-80, 1996.
158. Neuhausen SL, Swensen J, Miki Y, Liu Q, Tavtigian S, Shattuck-Eidens D, Kamb A, Hobbs MR, Gingrich J, Shizuya H, et al. A Pi-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1. Hum Mol Genet 3: 1919-26, 1994.
159. Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: Evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A 85: 3044-48, 1988.
160. Normand T, Narod S, Labrie F, Simard J. Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. Hum Mol Genet 2: 479-83, 1993.
161. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14: 188-90, 1996.
162. Offit K, Gilewski T, McGuire P, Schluger A, Hampel H, Brown K, Swensen J, Neuhausen S, Skolnick M, Norton L, Goldgar D. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 347: 1643-45, 1996.
163. Olopade OI. Genetics in clinical cancer care - the future is now. N Engl J Med 335: 1455-56, 1996.
164. Osborne-Lawrence S, Welcsh PL, Spillman M, Chandrasekharappa SC, Gallardo TD, Lovett M, Bowcock AM. Direct selection of expressed sequences within a 1-Mb region flanking BRCA1 on human chromosome 17q21. Genomics 25: 248-55, 1995.
165. Ostermeyer EA, Friedman LS, Lynch ED, Szabo CI, Dowd P, Lee MK, Rowell SE, King MC. Green pigs, red herrings, and a golden hoe: A retrospective on the identification of BRCA1 and the beginning of its characterization. Cold Spring Harb Symp Quant Biol 59: 523-30, 1994.
166. Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AM, Hogervorst F, Brohet R, Ligtenberg MJ, Teugels E, van der Luijt R, van der Hout AH, Gille JJ, Pals G, Jedema I, Olmer R, van Leeuwen I, Newman B, Plandsoen M, van der Est M, Brink G, Hageman S, Arts PJ, Bakker MM, Devilee P, et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60: 1041-49, 1997.
167. Peters JA. Familial cancer risk part II: Breast cancer risk counseling and genetic susceptibility testing. J Oncol Manag Nov/Dec: 14-22, 1994.
168. Peters JA, Stopfer JE. Role of the genetic counselor in familial cancer. Oncology 10: 159-78, 1996.
169. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heyboer H, Klijn JG, Vasen HF, Cornelisse CJ, van't Veer LJ, Bakker E, van Ommen GJ, Devilee P. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17: 341-45, 1997.
170. Rajan JV, Marquis ST, Gardner HP, Chodosh LA. Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Dev Biol 184: 385-401, 1997.
171. Rajan JV, Wang M, Marquis ST, Chodosh LA. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A 93: 13078-83, 1996.
172. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK, eds. SEER cancer statistics review, 1973-1994. NIH Pub. No. 97-2789. Bethesda, MD: National Cancer Institute, 1997.
173. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK. Surveillance, Epidemiology, and End Results (SEER) Program [web site]. Bethesda,
174. Risch N, de Leon D, Ozelius L, Kramer P, Almasy L, Singer B, Fahn S, Breakefield X, Bressman S. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet 9: 152-59, 1995.
175. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 273: 1516-17, 1996.
176. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14: 185-87, 1996.
177. Rommens JM, Durocher F, McArthur J, Tonin P, LeBlanc JF, Allen T, Samson C, Ferri L, Narod S, Morgan K, et al. Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21. Genomics 28: 530-42, 1995.
178. Rothenberg KH. Predictive genetic testing for cancer: Ethical, legal, social and public policy challenges. In: Fortner JG, Sharp PA, eds. Accomplishments in cancer research, 1995. Philadelphia: Lippincott, pp 209-13, 1996.
179. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL, Lynch HT, Boyd J. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335: 1413-16, 1996.
180. Schildkraut JM, Collins NK, Dent GA, Tucker JA, Barrett JC, Berchuck A, Boyd J. Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer. Am J Obstet Gynecol 172: 908-13, 1995.
181. Schrock E, Badger P, Larson D, Erdos M, Wynshaw-Boris A, Ried T, Brody L. The murine homolog of the human breast and ovarian cancer susceptibility gene Brca1 maps to mouse chromosome 11D. Hum Genet 97: 256-59, 1996.
182. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 94: 5605-10, 1997.
183. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88: 265-75, 1997.
184. Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, Schnitt S, Livingston DM. Location of BRCA1 in human breast and ovarian cancer cells. Science 272: 123-26, 1996.
185. Seitz S, Rohde K, Bender E, Nothnagel A, Kolble K, Schlag PM, Scherneck S. Strong indication for a breast cancer susceptibility gene on chromosome 8p 12-p22: Linkage analysis in German breast cancer families. Oncogene 14: 741-43, 1997.
186. Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM. Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancer-susceptibility genes? Am J Hum Genet 60: 486-95, 1997.
187. Shao N, Chai YL, Shyam E, Reddy P, Rao VN. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 13: 1-7, 1996.
188. Sharan SK, Bradley A. Murine Brca2: Sequence, map position, and expression pattern. Genomics 40: 234-41, 1997.
189. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386: 804-10, 1997.
190. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 273: 535-41, 1995.
191. Shiloh S. Decision-making in the context of genetic risk. In: Marteau T, Richards M, eds. The troubled helix. Cambridge: Cambridge University Press, pp 82-103, 1996.
192. Shiloh Y, Rotman G. Ataxia-telangiectasia and the ATM gene: Linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints. J Clin Immunol 16: 254-60, 1996.
193. Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc JF, Belanger C, Dion F, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 8: 392-98, 1994.
194. Smith SA, DiCioccio RA, Struewing JP, Easton DF, Gallion HH, Albertsen H, Mazoyer S, Johansson B, Steichen-Gersdorf E, Stratton M, et al. Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of ≤ 1 cM. Genes Chromosomes Cancer 10: 71-76, 1994.
195. Smith SA, Easton DF, Ford D, Peto J, Anderson K, Averill D, Stratton M, Ponder M, Pye C, Ponder BA. Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21. Am J Hum Genet 52: 767-76, 1993.
196. Smith TM, Lee MK, Szabo CI, Jerome N, McEuen M, Taylor M, Hood L, King MC. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res 6: 1029-49, 1996.
197. Spurr NK, Kelsell DP, Black DM, Murday VA, Turner G, Crockford GP, Solomon E, Cartwright RA, Bishop DT. Linkage analysis of early-onset breast and ovarian cancer families, with markers on the long arm of chromosome 17. Am J Hum Genet 52: 777-85, 1993.
198. Stratton MR, Ford D, Neuhasen S, Seal S, Wooster R, Friedman LS, King MC, Egilsson V, Devilee P, McManus R, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 7: 103-7, 1994.
199. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11: 198-200, 1995.
200. Struewing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA, Collins FS, Tucker MA. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 57: 1-7, 1995.
201. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-8, 1997.
202. Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, Nishina H, Chuang T, Wakeham A, Itie A, Koo W, Billia P, Ho A, Fukumoto M, Hui CC, Mak TW. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11: 1242-52, 1997.
203. Szabo CI, Wagner LA, Francisco LV, Roach JC, Argonza R, King MC, Ostrander EA. Human, canine and murine BRCA1 genes: Sequence comparison among species. Hum Mol Genet 5: 1289-98, 1996.
204. Tangir J, Muto MG, Berkowitz RS, Welch WR, Bell DA, Mok SC. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer. Oncogene 12: 735-40, 1996.
205. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Goldgar DE, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12: 333-37, 1996.
206. Teng DH, Bogden R, Mitchell J, Baumgard M, Bell R, Berry S, Davis T, Ha PC, Kehrer R, Jammulapati S, Chen Q, Offit K, Skolnick MH, Tavtigian SV, Jhanwar S, Swedlund B, Wong AK, Kamb A. Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 13: 241-44, 1996.
207. Thai HT, Du F, Tsan JT, Jin Y, Phung A, Spillman MA, Massa HF, Muller CY, Ashfaq R, Mathis MJ, Miller DS, Trask BJ, Baer R, Bowcock AM. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancer. Hum Mol Genet 7: 195-202, 1998.
208. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9: 444-50, 1995.
209. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13: 117-19, 1996.
210. Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, Tulinius H, Eyfjord JE. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60: 1079-84, 1997.
211. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi OP. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57: 1222-27, 1997.
212. Tonin P, Serova O, Lenoir G, Lynch H, Durocher F, Simard J, Morgan K, Narod S. BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet 57: 189, 1995.
213. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome - a molecular and clinical review. Br J Cancer 76: 1-14, 1997.
214. Vogelstein B, Kinzler KW. Has the breast cancer gene been found? Cell 79: 1-3, 1994.
215. Wagner TM, Moslinger R, Zielinski C, Scheiner O, Breiteneder H. New Austrian mutation in BRCA1 gene detected in three unrelated HBOC families. Lancet 347: 1263, 1996.
216. Waldholz M. Curing cancer: The story of the men and women unlocking the secrets of our deadliest illness. New York: Simon and Schuster, p 320, 1997.
217. Wang XW, Harris CC. TP53 tumour suppressor gene: Clues to molecular carcinogenesis and cancer therapy. Cancer Surv 28: 169-96, 1996.
218. Weatherall DJ. The new genetics and clinical practice. 3rd ed. Oxford: Oxford University Press, 1991.
219. Weber BL, Abel KJ, Couch FJ, Merajver SD, Chandrasekharappa SC, Castilla L, McKinley DAUHPP, Calzone K, Frank TS, et al. Progress toward isolation of a breast cancer susceptibility gene, BRCA1. Cold Spring Harb Symp Quant Biol 59: 531-36, 1994.
220. Weissenbach J. A second generation linkage map of the human genome based on highly informative microsatellite loci. Gene 135: 275-78, 1993.
221. Welsh MJ, Tsui L-C, Boat TF, Beaudet AL. Cystic Fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. Vol. 3. 7th ed. New York: McGraw-Hill, pp 3799-3878, 1995.
222. Whittemore AS. Risk of breast cancer in carriers of BRCA gene mutations. N Engl J Med 337: 788-89, 1997.
223. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60: 496-504, 1997.
224. Whittemore AS, Henderson BE. Dietary fat and breast cancer: Where are we? J Natl Cancer Inst 85: 762-63; discussion 764-65, 1993.
225. Wilfond BS, Rothenberg KH, Thomson EJ, Lerman C. Cancer genetic susceptibility testing: Ethical and policy implications for future research and clinical practice. J Law Med Ethics 25: 243-51, 1997.
226. Wong AKC, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2. J Biol Chem 272: 31941-44, 1997.
227. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2 [published erratum appears in Nature 379: 749, 1996). Nature 378: 789-92, 1995.
228. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265: 2088-90, 1994.
229. Wooster R, Stratton MR. Breast cancer susceptibility: A complex disease unravels. Trends Genet 11: 3-5, 1995.
230. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14: 430-40, 1996.
231. Zelada-Hedman M, Torroella M, Mesquita R, Nordenskjold M, Skoog L, Lindblom A. Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome. Hum Genet 94: 231-34, 1994.